neobookRx
DrugsLevel 4 LocalisationS3TABEML

Nebivolol

Selective beta blockerAntihypertensive

Indications

Registered South African indications:

  • Hypertension

Cautions

Contraindications

  • Hypersensitivity to the active ingredient or any of its excipients
  • Liver insufficiency or liver function impairment
  • Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring IV inotropic therapy
  • Pregnancy
  • Breastfeeding
  • Cardiogenic shock
  • Uncontrolled heart failure
  • Sick sinus syndrome, including sino-atrial block
  • Second- and third-degree heart block (without a pacemaker)
  • History of bronchospasm and bronchial asthma
  • Untreated phaeochromocytoma
  • Metabolic acidosis
  • Bradycardia (heart rate <60bpm prior to start of therapy)
  • Hypotension (systolic blood pressure <90mm Hg)
  • Severe peripheral circulatory disturbances
  • In combination with verapamil therapy

Cautions

  • Severe renal impairment
  • Elderly
  • Unstable congestive cardiac failure
  • Ischaemic heart disease
  • First degree heart block
  • Vasospastic (Prinzmetal's) angina
  • Diabetes mellitus
  • Hyperthyroidism
  • Chronic obstructive pulmonary disease
  • Psoriasis
  • History of allergic reactions
  • Abruption cessation
  • Galactose intolerance
  • Lapp lactase deficiency 
  • Glucose-galactose malabsorption

Adult dosage

Forms avail. in SA and covered in this monograph: tab

Hypertension - mild, moderate

  • Oral (tab): 5mg, dly

Cardiac failure

  • Oral (tab): 1.25mg, dly; Titrate by doubling dose at 1-2 week intervals; Maintenance: 10mg, dly; Max dose: 10mg/24hrs

Paediatric dosage

Not established for use in children below 18 years

Special populations

Pregnancy

  • Contraindicated

Breastfeeding

  • Contraindicated

Renal Impairment

  • Severe: Caution; no information available

Hepatic Impairment

  • Contraindicated 
    Contraindicated for liver insufficiency or liver function impairment

Elderly

  • Caution; dose adjustment recommended

Adverse reactions

Central Nervous System Disorders

  • Nightmares
  • Depression
  • Headache
  • Dizziness 
  • Paraesthesia 
  • Syncope

Cardiovascular Disorders

  • Bradycardia 
  • Heart failure
  • Slowed atrioventricular conduction
  • Atrioventricular block
  • Hypotension 
  • Intermittent claudication

Respiratory Disorders

  • Dyspnoea
  • Bronchospasm

Gastrointestinal Disorders

  • Constipation 
  • Nausea and vomiting
  • Diarrhoea
  • Dyspepsia 
  • Flatulence

Genitourinary Disorders

  • Impotence

Skin and Subcutaneous Tissue Disorders

  • Pruritus 
  • Rash
  • Psoriasis
  • Urticaria

Immune, Blood and Lymphatic System Disorders

  • Angioneurotic oedema
  • Hypersensitivity

Interactions

  • Class I antiarrythmics
  • Calcium channel blockers
  • Verapamil
  • Centrally-acting antihypertensives
  • Amioderone
  • Halogenated anaesthetics
  • Insulin
  • Antidiabetic agents
  • Baclofen
  • Amifostine
  • Digoxin
  • Antipsychotics
  • Antidepressants
  • Non-steroidal anti-inflammatory drugs
  • Sympathomimetics
  • Cimetidine
  • Nicardipine 

Monitoring

None routine. Specific cases may require

  • Blood glucose
  • ECG

Mechanism of action

Nebivolol is a competitive and selective beta-receptor antagonist which has mild vasodilating properties.

Dosage forms

  • Tablet

Formulation

Tablet 5mg

  • Lovispes (Akacia) originator
  • Nebilet (Adcock) originator

References

1. https://www.medicines.org.uk/emc/medicine/9145 10 February 2015 A. Menarini Farmaceutica Internazionale SRL 5mg tablet 2. https://www.medicines.org.uk/emc/medicine/26209 22 April 2015 Zentiva 3. SAMF_Page 155 4. http://home.intekom.com/pharm/adcock/nebilet.html 5. https://drive.google.com/drive/folders/10Gsqh9X1Io7z8MYdQLU-OUCaQC48i_SY (1/11/2000_Adcock_Nebilet_5mg_tab) 6. https://drive.google.com/drive/folders/10Gsqh9X1Io7z8MYdQLU-OUCaQC48i_SY (02/02/2015_Akacia_Lovispes_tab) 7. PI - NEBILET 5 mg tablets, LeBasi Pharmaceuticals (Pty) Ltd - DATE OF REVISION OF THE TEXT 18 April 2024 Downloaded from SAHPRA 16 Oct 2024 [https://pi-pil-repository.sahpra.org.za/wp-content/uploads/2024/05/PI_Nebilet-340495_18.04.2024.pdf]

Brands & products

2 products · stale NAPPI snapshot · refreshed 5/28/2026 · 159 days old

tabletGeneric· 2 products

from R8.44/unit
ProductStrengthPackSchedSEPUnitDisp feeNAPPI
Nebilet5 mg30S3R253.21R8.44R94.87700558003
Lovispes5 mg30S3R372.67R12.42R127.73716483001
Trade names (2)
  • Lovispes
  • Nebilet

Medical aid coverage

data not yet integrated
Discovery Health
not yet integrated
  • Comprehensive Series—
  • Executive Plan—
  • KeyCare Series—
  • Priority Series—
  • Saver Series—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

Bonitas Medical Fund
not yet integrated
  • BonClassic—
  • BonComprehensive—
  • BonEssential—
  • BonFit Select—
  • BonSave—
  • BonStart—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

GEMS — Government Employees Medical Scheme
not yet integrated
  • Beryl—
  • Emerald—
  • Onyx—
  • Ruby—
  • Sapphire—
  • Tanzanite One—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

POLMED — Police Medical Aid Scheme
not yet integrated
  • Aquarium Option—
  • Efficiency Option—
  • Marine Option—

Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.

Interacts with 4 known drugs

Check against other drugs →
NeoHealth® ID 15752 · updated 2/12/2026